8521 Background: The combination of chemotherapy and immunotherapy (CT-IO) has a
high response rate and longer survival in unselected patients (pts) with metastatic non-small …

8501 Background: Non-small cell lung cancer (NSCLC) is incurable in most patients with
locally advanced stage IIIA disease. Previous results indicate that the use of neoadjuvant …

Background While osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-…

Introduction: Lung cancer is the most important cause of cancer mortality. It is a multifactorial
disease with multiple risk factors, including residential radon exposure. Areas covered: The …

OBJECTIVES This analysis aimed to evaluate perioperative outcomes of surgical resection
following neoadjuvant treatment with chemotherapy plus nivolumab in resectable stage IIIA …

TPS8581 Background: The results of current studies are considered acceptable evidence to
support the hypothesis of efficacy of the proposed combination of immunotherapy with …

We read with great interest the Policy Review by Oudkerk and colleagues, 1 but we do not
agree with their conclusion that lung cancer screening should be implemented in Europe. We …

Hodgkin's lymphoma represents one of the most frequent lymphoproliferative syndromes,
especially in young population. Although HL is considered one of the most curable tumors, a …

LBA8511 Background: Several studies have shown an association of pathological response,
a common efficacy endpoint in neoadjuvant therapy trials, with survival for chemo in …

PURPOSE The combination of zanubrutinib plus obinutuzumab (ZO) was found to be well
tolerated with an early signal of efficacy in a phase Ib study. ROSEWOOD is a phase II, …